No Prescription |
 |
 | ||
|
Acivir DT Zovirax |
|
| ||
No Prescription » Prescription Drugs 1 » Acivir DT Zovirax Aciclovir is used for: Treating chickenpox (varicella) or shingles (herpes zoster) and treating or suppressing genital herpes infections. Aciclovir is an antiviral drug. It slows the growth and spread of the herpes virus so that the body can fight off the infection.Aciclovir will not cure herpes but it can lessen the symptoms of the infection. Acyclovir is used to treat infections caused by herpes viruses. Buy Acivir DT Zovirax and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About Acivir DT Zovirax: Product Type: Prescription Drugs 1 Acivir DT ( Zovirax Generic Aciclovir ) Acivir DT (Zovirax Generic Aciclovir) Zovirax Generic Aciclovir 200mg 400(4 x 100) Tablets 200mg 100 Tablets 200mg 200(2 x 100) Tablets 400mg 50 Tablets 400mg 100(2 x 50) Tablets 400mg 200(4 x 50) Tablets Zovirax Generic Aciclovir Acivir DT
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
